Sibel Health, a Northwestern University spin-out, has secured $30 million in a Series C funding round led by the Steele Foundation for Hope, with participation from Drger. This financial boost coincides with the company’s seventh FDA clearance. The Chicago-based firm’s ANNE One platform, equipped with advanced wearable sensors, AI-enabled data analytics, and an integrated mobile and cloud system, now supports wireless monitoring of vital signs for patients aged 12 and older. The platform’s components, the Anne Limb and Anne Chest, measure various health metrics including skin and body temperature, heart and respiratory rates, step count, and fall count. The latest FDA 510(k) clearance enhances the platform with alarms, alerts, and a central station. Sibel Health plans to use the new funds to accelerate the commercial rollout of ANNE One. The company also noted that nearly one million hospital beds in the U.S. lack continuous monitoring, and most patient deaths occur outside ICUs. In other developments, Sibel Health partnered with Denmark’s capital region and Drger for long-term hospital monitoring projects. In 2023, they launched the Discovery platform for clinical trials and received FDA clearance for neonate monitoring up to age two. Previous funding includes a $33 million Series B in 2022 and a $10 million Series A led by Drger.
Source: www.mobihealthnews.com















